Sign in to confirm you’re not a bot
This helps protect our community. Learn more

Anti-CD7 CAR-T therapy for T-ALL/LBL

VJHemOnc – Video Journal of Hematology & HemOnc
14.9K subscribers
<__slot-el>
<__slot-el>
151 views 1 year ago
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, reports encouraging efficacy of an anti-CD7 CAR-T treatment for T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL). Although outcomes for these patients are usually poor once they have relapsed, this agent achieved a favorable two-year overall survival (OS) and a disease-free survival (DFS) higher than 50%. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved. ...more
...more
Comments are turned off. Learn more
Anti-CD7 CAR-T therapy for T-ALL/LBL
3Likes
151Views
2024Feb 13
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, reports encouraging efficacy of an anti-CD7 CAR-T treatment for T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL). Although outcomes for these patients are usually poor once they have relapsed, this agent achieved a favorable two-year overall survival (OS) and a disease-free survival (DFS) higher than 50%. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Follow along using the transcript.

VJHemOnc – Video Journal of Hematology & HemOnc

14.9K subscribers